ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 54

Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study

Il Woong Sohn1, Young Bin Joo1, Soyoung Won2, Seung Taek Song1, Seung Lee3, Hye-Jin Jeong3 and Sang-Cheol Bae1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, outcomes and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that affects frequently in their 20s and 30s. However, SLE could develop in other age group such as childhood-onset or late-onset. We aimed to investigate the influence of age of disease onset on clinical features, disease activity, and outcomes in adult patients with SLE.

Methods: We analyzed 917 adult patients with SLE from 1998 to 2012. The patients were classified into two groups based on the age at disease diagnosis: adult-onset SLE (≥18 and <50 years) and late-onset SLE (≥50 years). The American College of Rheumatology (ACR) criteria for SLE classification, the SLE Disease Activity Index (SLEDAI-2K), adjusted mean SLEDAI-2K (AMS), incidence rate of SLE flares (defined by ≥4 points increase of the SLEDAI-2K compared with that of previous visit), and prescribed medication were compared between two groups. As outcomes, organ damage and mortality were compared using SLICC/ACR Damage Index (SDI) and age- and sex adjusted standardized mortality ratio (SMR), respectively.

Results: Of the 917 SLE patients, 885 (91.4%) patients were adult-onset (mean age 29.4, range 18-49 years) and 32 (3.5%) patients were late-onset (mean age 55, range 50-68 years). After the mean follow-up years of 6.4, the number of cumulative ACR criteria was significantly lower in patients with late-onset compared with adult-onset SLE (4.6±1.2 vs 5.5±1.4, p<0.001). The mean SLEDAI-2K at enrollment (3.3±2.9 vs 5.4±4.2, p<0.001) and adjusted mean SLEDAI-2K over time (2.7±2.1 vs 4.3±2.6, p<0.001) were significantly lower in patients with late-onset compared with adult-onset SLE. The incidence rate ratio of SLE flares (late-onset/adult-onset SLE patients) was 0.44. The use of glucocorticoids and immunosuppressants was similar between two groups, but the use of azathioprine was lower in late-onset SLE patients (9.4% vs 29.8%, p=0.021). The percentage of cumulative SDI≥1 was higher in patients with late-onset compared with adult-onset SLE, but none reached statistical significance (50% vs 43.4%, p=0.576). A total of 42 patients died (6 in late-onset and 36 in adult-onset SLE group). The leading cause of death in both groups was SLE-related diseases, followed by infection. As compared to general population, the age- and sex adjusted SMR in late-onset and adult-onset SLE group was 1.58 (95% CI 0.58-3.43) and 3.34 (95% CI 2.34-4.63), respectively.

Conclusion: Compared with adult-onset SLE, late-onset SLE showed significantly mild clinical features and lower disease activity during follow-up. However, the percentage of patients with organ damage in patients with late-onset SLE was similar to that of adult-onset. The mortality of late-onset SLE was not higher than general population, although the mortality of adult-onset was three times higher than general population. Our results suggest that the clinical prognosis of late-onset SLE is better than adult-onset SLE.

 

ACR criteria

AMS

SDI

Age- and sex adjusted SMR

 

mean±SD

p-value

mean±SD

p-value

mean±SD

p-value

(95% CI)

Adult-onset

5.5±1.4

<0.001

4.3±2.6

<0.001

0.9±1.5

0.933

3.34(2.34-4.63)

Late-onset

4.6±1.2

2.7±2.1

0.9±1.2

1.58(0.58-3.43)


Disclosure: I. W. Sohn, None; Y. B. Joo, None; S. Won, None; S. T. Song, None; S. Lee, None; H. J. Jeong, None; S. C. Bae, Bristol-Myers Squibb, 2.

To cite this abstract in AMA style:

Sohn IW, Joo YB, Won S, Song ST, Lee S, Jeong HJ, Bae SC. Impact of Age at Disease Diagnosis on Clinical Manifestations, Disease Activity, and Outcomes in Patients with Systemic Lupus Erythematosus: Single-Center Prospective Cohort Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/impact-of-age-at-disease-diagnosis-on-clinical-manifestations-disease-activity-and-outcomes-in-patients-with-systemic-lupus-erythematosus-single-center-prospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-age-at-disease-diagnosis-on-clinical-manifestations-disease-activity-and-outcomes-in-patients-with-systemic-lupus-erythematosus-single-center-prospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology